NanoViricides, Inc.(NNVC)Earnings, Financials & Key Ratios
NNVC•AMEX
$1.42
$31M mkt cap·Price updated May 7, 2026
AboutNanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.Show more
- Revenue$0
- EBITDA-$9M-14.1%
- Net Income-$9M-14.1%
- EPS (Diluted)-0.63+10.0%
- ROE-99.75%-58.3%
- ROIC-113.96%-19.4%
NNVC Key Insights
NanoViricides, Inc. (NNVC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 27.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NNVC Price & Volume
NanoViricides, Inc. (NNVC) stock price & volume — 10-year historical chart
Loading chart...
NNVC Growth Metrics
NanoViricides, Inc. (NNVC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23713523.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM34.25%
Return on Capital
10 Years-49.03%
5 Years-54.42%
3 Years-69.2%
Last Year-101.06%
NNVC Peer Comparison
NanoViricides, Inc. (NNVC) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SIGA | 338.88M | 4.73 | 14.33 | -31.8% | -43117.39% | -10.67% | 0.00 | |
 COCP | 18.13M | 1.39 | -0.81 | -126.11% | 0.19 | |||
 GILD | 166.4B | 134.06 | 19.77 | 2.4% | 30.99% | 42.33% | 1.09 | |
 ABBV | 358.42B | 202.64 | 85.50 | 8.57% | 6.91% | 62.15% | ||
 RGEN | 7.13B | 126.43 | 147.01 | 16.36% | 6.73% | 2.46% | 0.33 | |
 NVAX | 1.5B | 9.23 | 3.63 | 64.69% | -14.73% | |||
 VXRT | 177.97M | 0.74 | 10.57 | 7.27% | 6.88% | 33.83% | 0.10 | |
 IBRX | 7.64B | 7.76 | -12.52 | 22.71% | -422.28% |
Compare NNVC vs Peers
NanoViricides, Inc. (NNVC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NNVC Income Statement
NanoViricides, Inc. (NNVC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 662.95K | 680.06K | 695.91K | 0 | 0 | 0 | 0 | 0 | 0 | 265.9K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -662.95K▲ 0% | -680.06K▼ 2.6% | -695.91K▼ 2.3% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -265.9K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -0.52% | -2.58% | -2.33% | 100% | - | - | - | - | - | - |
| Operating Expenses | 9.6M | 9.33M | 8.66M | 8M | 8.74M | 8.11M | 8.94M | 8.52M | 9.59M | 2.23T |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.07M | 4.5M | 2.74M | 3.3M | 2.63M | 2.33M | 2.55M | 3.08M | 4.04M | 1.11T |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 5.53M | 4.83M | 5.92M | 4.7M | 6.11M | 5.78M | 6.39M | 5.44M | 5.55M | 1.12T |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -9.6M▲ 0% | -9.33M▲ 2.9% | -8.66M▲ 7.1% | -8M▲ 7.7% | -8.74M▼ 9.3% | -8.11M▲ 7.2% | -8.94M▼ 10.2% | -8.52M▲ 4.8% | -9.59M▼ 12.6% | -8.39M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -8.37% | 2.87% | 7.14% | 7.66% | -9.35% | 7.21% | -10.23% | 4.78% | -12.63% | - |
| EBITDA | -8.94M | -8.65M | -7.96M | -7.3M | -8.04M | -7.39M | -8.2M | -7.76M | -8.85M | -7.78M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -9% | 3.27% | 7.88% | 8.38% | -10.18% | 8.08% | -10.9% | 5.35% | -14.06% | 11.17% |
| D&A (Non-Cash Add-back) | 662.95K | 680.06K | 695.91K | 699.72K | 704.54K | 723.33K | 747.53K | 759.01K | 743.8K | 618.21K |
| EBIT | -9.6M | -9.27M | -8.66M | -8M | -8.74M | -8.1M | -8.59M | -8.24M | -9.47M | -8.33M |
| Net Interest Income | -2.07M | -444.06K | 55.5K | -76.59K | -76.06K | 6.74K | 354.89K | 221.97K | 124.83K | 76.18K |
| Interest Income | 60.95K | 100.43K | 55.5K | 17.08K | 9.35K | 11.86K | 355.83K | 271.77K | 124.83K | 76.18K |
| Interest Expense | 2.13M | 544.49K | 0 | 93.67K | 85.41K | 5.12K | 938 | 49.81K | 0 | 0 |
| Other Income/Expense | -703.77K | 761.71K | 235.24K | -5.45M | -78.08K | 6.74K | 354.89K | 221.97K | 124.68K | 76.18K |
| Pretax Income | -10.3M▲ 0% | -8.56M▲ 16.9% | -8.42M▲ 1.6% | -13.45M▼ 59.6% | -8.82M▲ 34.4% | -8.11M▲ 8.1% | -8.59M▼ 5.9% | -8.29M▲ 3.4% | -9.47M▼ 14.1% | -8.32M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | -179.75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 2.13% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -10.3M▲ 0% | -8.56M▲ 16.9% | -8.24M▲ 3.7% | -13.45M▼ 63.1% | -8.82M▲ 34.4% | -8.11M▲ 8.1% | -8.59M▼ 5.9% | -8.29M▲ 3.4% | -9.47M▼ 14.1% | -2.22T▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 3.92% | 16.9% | 3.72% | -63.09% | 34.39% | 8.11% | -5.94% | 3.43% | -14.14% | -23713523.33% |
| Net Income (Continuing) | -10.3M | -8.56M | -8.42M | -13.45M | -8.82M | -8.11M | -8.59M | -8.29M | -9.47M | -8.32M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.43▲ 0% | -2.64▲ 23.0% | -2.30▲ 12.9% | -2.39▼ 3.9% | -0.81▲ 66.1% | -0.70▲ 13.6% | -0.74▼ 5.7% | -0.70▲ 5.4% | -0.63▲ 10.0% | -111875.32▲ 0% |
| EPS Growth % | 7.8% | 23.03% | 12.88% | -3.91% | 66.11% | 13.58% | -5.71% | 5.41% | 10% | 34.25% |
| EPS (Basic) | -3.43 | -2.64 | -2.30 | -2.39 | -0.81 | -0.70 | -0.74 | -0.70 | -0.63 | - |
| Diluted Shares Outstanding | 3.01M | 3.25M | 3.59M | 5.62M | 10.9M | 11.53M | 11.63M | 11.87M | 15.12M | 19.85M |
| Basic Shares Outstanding | 3.01M | 3.25M | 3.59M | 5.62M | 10.9M | 11.53M | 11.63M | 11.87M | 15.12M | 19.85M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NNVC Balance Sheet
NanoViricides, Inc. (NNVC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.29M | 7.32M | 2.83M | 13.99M | 20.82M | 14.42M | 8.45M | 4.97M | 1.67M | 5.3T |
| Cash & Short-Term Investments | 15.1M | 7.08M | 2.56M | 13.71M | 20.52M | 14.07M | 8.15M | 4.8M | 1.56M | 5.15T |
| Cash Only | 15.1M | 7.08M | 2.56M | 13.71M | 20.52M | 14.07M | 8.15M | 4.8M | 1.56M | 5.15T |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 145.99B |
| Total Non-Current Assets | 11.71M | 11.22M | 10.62M | 9.93M | 9.44M | 9.08M | 8.45M | 7.85M | 7.15M | 6.97T |
| Property, Plant & Equipment | 11.27M | 10.84M | 10.23M | 9.54M | 9.08M | 8.69M | 8.11M | 7.51M | 6.83M | 6.66T |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 383.2K | 374.93K | 366.66K | 358.39K | 350.12K | 341.85K | 333.58K | 325.31K | 317.04K | 312.9B |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 58.93K | 8.16K | 29.19K | 25.86K | 3.52K | 42.44K | 14.36K | 14.56K | 2.44K | 1.73B |
| Total Assets | 27M▲ 0% | 18.55M▼ 31.3% | 13.45M▼ 27.5% | 23.91M▲ 77.8% | 30.26M▲ 26.5% | 23.49M▼ 22.4% | 16.9M▼ 28.1% | 12.82M▼ 24.1% | 8.82M▼ 31.2% | 12.27T▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -26.29% | -31.32% | -27.49% | 77.82% | 26.54% | -22.36% | -28.07% | -24.12% | -31.18% | 99999827.5% |
| Total Current Liabilities | 4.67M | 881.95K | 2.85M | 2.16M | 351.15K | 412.84K | 534.25K | 1.36M | 1.31M | 1.2T |
| Accounts Payable | 135.79K | 223.34K | 309.89K | 380.73K | 200.02K | 57.96K | 157.06K | 376.27K | 1.28M | 218.31B |
| Days Payables Outstanding | 74.76 | 119.87 | 162.54 | - | - | - | - | - | - | 74.92M |
| Short-Term Debt | 3.96M | 0 | 0 | 1.14M | 95.31K | 94.79K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 541.37K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 539.58K | 638.89K | 2.53M | 592.58K | 0 | 214.4K | 338.13K | 958.97K | 0 | 977.61B |
| Current Ratio | 3.28x | 8.30x | 0.99x | 6.49x | 59.30x | 34.92x | 15.81x | 3.66x | 1.28x | 1.28x |
| Quick Ratio | 3.28x | 8.30x | 0.99x | 6.49x | 59.30x | 34.92x | 15.81x | 3.66x | 1.28x | 1.28x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.02M | 0 | 0 | 0 | 0 | 0 | 1.5M | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.02M | 0 | 0 | 0 | 0 | 0 | 1.5M | 0 | 0 | 0 |
| Total Liabilities | 6.68M | 881.95K | 2.85M | 2.16M | 351.15K | 412.84K | 2.03M | 1.36M | 1.31M | 1.2T |
| Total Debt | 3.96M | 0 | 0 | 1.14M | 95.31K | 94.79K | 0 | 0 | 0 | 0 |
| Net Debt | -11.14M | -7.08M | -2.56M | -12.56M | -20.42M | -13.97M | -8.15M | -4.8M | -1.56M | -5.15T |
| Debt / Equity | 0.19x | - | - | 0.05x | 0.00x | 0.00x | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 662334.33x |
| Interest Coverage | -4.51x | -17.13x | - | -85.37x | -102.38x | -1583.76x | -9534.61x | -170.98x | - | - |
| Total Equity | 20.32M▲ 0% | 17.66M▼ 13.1% | 10.6M▼ 40.0% | 21.76M▲ 105.3% | 29.91M▲ 37.5% | 23.08M▼ 22.8% | 14.87M▼ 35.6% | 11.46M▼ 22.9% | 7.52M▼ 34.4% | 11.07T▲ 0% |
| Equity Growth % | -11.83% | -13.08% | -39.99% | 105.26% | 37.47% | -22.83% | -35.6% | -22.88% | -34.42% | 99999819.48% |
| Book Value per Share | 6.76 | 5.44 | 2.95 | 3.87 | 2.74 | 2.00 | 1.28 | 0.97 | 0.50 | 557769.02 |
| Total Shareholders' Equity | 20.32M | 17.66M | 10.6M | 21.76M | 29.91M | 23.08M | 14.87M | 11.46M | 7.52M | 11.07T |
| Common Stock | 63.3K | 69.17K | 76.9K | 9.08K | 11.52K | 116 | 116 | 131 | 166 | 216M |
| Retained Earnings | -75.13M | -83.69M | -92.12M | -105.56M | -114.39M | -122.49M | -131.08M | -139.37M | -148.84M | -152.85T |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NNVC Cash Flow Statement
NanoViricides, Inc. (NNVC) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.9M | -7.78M | -6.8M | -6.67M | -8.21M | -5.89M | -5.67M | -6.32M | -8.48M | -8.48M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -15.65% | 1.54% | 12.51% | 2.02% | -23.23% | 28.28% | 3.75% | -11.38% | -34.25% | 27.69% |
| Net Income | -10.3M | -8.56M | -8.42M | -13.45M | -8.82M | -8.11M | -8.59M | -8.29M | -9.47M | -2.22T |
| Depreciation & Amortization | 662.95K | 680.06K | 695.91K | 699.72K | 704.54K | 723.33K | 747.53K | 759.01K | 743.8K | 261.77B |
| Stock-Based Compensation | 1.6M | 791.16K | 532.32K | 559.4K | 405.59K | 338.42K | 214.18K | 222.19K | 223.35K | 23.22B |
| Deferred Taxes | -1.33M | -1.14M | -191.66K | 5.24M | 8.13K | 0 | -99.1K | 0 | 0 | 0 |
| Other Non-Cash Items | 1.95M | 419.49K | 17.39K | 163.96K | 30.2K | 939.3K | 257.1K | 563 | 679 | 3.72T |
| Working Capital Changes | -485.86K | 32.38K | 567.71K | 119.66K | -540.11K | 214.56K | 1.8M | 996.88K | 20.46K | 5.79K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -387.5K | -145.67K | 802.87K | 110.63K | -710.75K | 40.8K | 118.13K | 705.82K | 184.24K | 28.91K |
| Cash from Investing | -164.98K | -241.82K | -73.79K | -8.64K | -238.76K | -324.35K | -151.71K | -156.56K | -56.96K | -84.32B |
| Capital Expenditures | -164.98K | -241.82K | -73.79K | -8.64K | -238.76K | -324.35K | -151.71K | -156.56K | -56.96K | -84.32B |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -1M | 4.61M | 2.35M | 17.83M | 15.26M | -234.72K | -94.79K | 3.12M | 5.3M | 8.62M |
| Debt Issued (Net) | -1M | 0 | 0 | 1.16M | -1.3M | -234.72K | -94.79K | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 0 | 0 | 1000K | 1000K | 3.3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -4.61M | 0 | -12.19K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -9.06M▲ 0% | -8.02M▲ 11.5% | -4.53M▲ 43.5% | 11.15M▲ 346.4% | 6.81M▼ 39.0% | -6.45M▼ 194.7% | -5.92M▲ 8.3% | -3.35M▲ 43.3% | -3.24M▲ 3.4% | 5.15T▲ 0% |
| Free Cash Flow | -8.06M▲ 0% | -8.02M▲ 0.6% | -6.88M▲ 14.2% | -6.67M▲ 2.9% | -8.45M▼ 26.6% | -6.22M▲ 26.5% | -5.82M▲ 6.3% | -6.47M▼ 11.2% | -8.54M▼ 31.9% | -3.73T▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -10.36% | 0.56% | 14.23% | 2.94% | -26.65% | 26.47% | 6.34% | -11.17% | -31.88% | -44377765.82% |
| FCF per Share | -2.68 | -2.47 | -1.92 | -1.19 | -0.78 | -0.54 | -0.50 | -0.55 | -0.56 | -0.56 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.91x | 0.83x | 0.50x | 0.93x | 0.73x | 0.66x | 0.76x | 0.90x | 1.68x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 149 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NNVC Key Ratios
NanoViricides, Inc. (NNVC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -47.52% | -45.09% | -58.34% | -83.11% | -34.15% | -30.6% | -45.27% | -63% | -99.75% | -20.06% |
| Return on Invested Capital (ROIC) | -86.37% | -70.78% | -69.73% | -69.58% | -70.2% | -65.43% | -84.77% | -95.46% | -113.96% | -113.96% |
| Debt / Equity | 0.19x | - | - | 0.05x | 0.00x | 0.00x | - | - | - | 0.00x |
| Interest Coverage | -4.51x | -17.13x | - | -85.37x | -102.38x | -1583.76x | -9534.61x | -170.98x | - | - |
| FCF Conversion | 0.77x | 0.91x | 0.83x | 0.50x | 0.93x | 0.73x | 0.66x | 0.76x | 0.90x | 1.68x |
NNVC Frequently Asked Questions
NanoViricides, Inc. (NNVC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NanoViricides, Inc. (NNVC) grew revenue by 0.0% over the past year. Growth has been modest.
NanoViricides, Inc. (NNVC) reported a net loss of $2.22T for fiscal year 2025.
Dividend & Returns
NanoViricides, Inc. (NNVC) has a return on equity (ROE) of -99.7%. Negative ROE indicates the company is unprofitable.
NanoViricides, Inc. (NNVC) had negative free cash flow of $3.73T in fiscal year 2025, likely due to heavy capital investments.
Explore More NNVC
NanoViricides, Inc. (NNVC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates